Asma Siddique1, James E Nelson2, Bradley Aouizerat3, Matthew M Yeh4, Kris V Kowdley5. 1. Liver Center of Excellence, Digestive Disease Institute, Virginia Mason Medical Center, Seattle, Washington. 2. Liver Center of Excellence, Digestive Disease Institute, Virginia Mason Medical Center, Seattle, Washington; Benaroya Research Institute, Virginia Mason Medical Center, Seattle, Washington. 3. Department of Physiological Nursing and Institute for Human Genetics, University of California at San Francisco, San Francisco, California. 4. Department of Pathology, University of Washington School of Medicine, Seattle, Washington. 5. Liver Center of Excellence, Digestive Disease Institute, Virginia Mason Medical Center, Seattle, Washington; Benaroya Research Institute, Virginia Mason Medical Center, Seattle, Washington. Electronic address: Kris.kowdley@vmmc.org.
Abstract
BACKGROUND & AIMS: Iron deficiency is often observed in obese individuals. The iron regulatory hormone hepcidin is regulated by iron and cytokines interleukin (IL) 6 and IL1β. We examine the relationship between obesity, circulating levels of hepcidin, and IL6 and IL1β, and other risk factors in patients with nonalcoholic fatty liver disease (NAFLD) with iron deficiency. METHODS: We collected data on 675 adult subjects (>18 years old) enrolled in the Nonalcoholic Steatohepatitis Clinical Research Network. Subjects with transferrin saturation <20% were categorized as iron deficient, whereas those with transferrin saturation ≥20% were classified as iron normal. We assessed clinical, demographic, anthropometric, laboratory, dietary, and histologic data from patients, and serum levels of hepcidin and cytokines IL6 and IL1β. Univariate and multivariate analysis were used to identify risk factors for iron deficiency. RESULTS: One-third of patients (231 of 675; 34%) were iron deficient. Obesity, diabetes, and metabolic syndrome were more common in subjects with iron deficiency (P < .01), compared with those that were iron normal. Serum levels of hepcidin were significantly lower in subjects with iron deficiency (61 ± 45 vs 81 ± 51 ng/mL; P < .0001). Iron deficiency was significantly associated with female gender, obesity, increased body mass index and waist circumference, presence of diabetes, lower alcohol consumption, black or American Indian/Alaska Native race (P ≤ .018), and increased levels of IL6 and IL1β (6.6 vs 4.8 for iron normal, P ≤ .0001; and 0.45 vs 0.32 for iron normal, P ≤ .005). CONCLUSIONS: Iron deficiency is prevalent in patients with NAFLD and associated with female gender, increased body mass index, and nonwhite race. Serum levels of hepcidin were lower in iron-deficient subjects, reflecting an appropriate physiologic response to decreased circulating levels of iron, rather than a primary cause of iron deficiency in the setting of obesity and NAFLD.
BACKGROUND & AIMS:Iron deficiency is often observed in obese individuals. The iron regulatory hormone hepcidin is regulated by iron and cytokines interleukin (IL) 6 and IL1β. We examine the relationship between obesity, circulating levels of hepcidin, and IL6 and IL1β, and other risk factors in patients with nonalcoholic fatty liver disease (NAFLD) with iron deficiency. METHODS: We collected data on 675 adult subjects (>18 years old) enrolled in the Nonalcoholic Steatohepatitis Clinical Research Network. Subjects with transferrin saturation <20% were categorized as iron deficient, whereas those with transferrin saturation ≥20% were classified as iron normal. We assessed clinical, demographic, anthropometric, laboratory, dietary, and histologic data from patients, and serum levels of hepcidin and cytokines IL6 and IL1β. Univariate and multivariate analysis were used to identify risk factors for iron deficiency. RESULTS: One-third of patients (231 of 675; 34%) were iron deficient. Obesity, diabetes, and metabolic syndrome were more common in subjects with iron deficiency (P < .01), compared with those that were iron normal. Serum levels of hepcidin were significantly lower in subjects with iron deficiency (61 ± 45 vs 81 ± 51 ng/mL; P < .0001). Iron deficiency was significantly associated with female gender, obesity, increased body mass index and waist circumference, presence of diabetes, lower alcohol consumption, black or American Indian/Alaska Native race (P ≤ .018), and increased levels of IL6 and IL1β (6.6 vs 4.8 for iron normal, P ≤ .0001; and 0.45 vs 0.32 for iron normal, P ≤ .005). CONCLUSIONS:Iron deficiency is prevalent in patients with NAFLD and associated with female gender, increased body mass index, and nonwhite race. Serum levels of hepcidin were lower in iron-deficient subjects, reflecting an appropriate physiologic response to decreased circulating levels of iron, rather than a primary cause of iron deficiency in the setting of obesity and NAFLD.
Authors: James E Nelson; Laura Wilson; Elizabeth M Brunt; Matthew M Yeh; David E Kleiner; Aynur Unalp-Arida; Kris V Kowdley Journal: Hepatology Date: 2010-11-29 Impact factor: 17.425
Authors: A Stadlmayr; E Aigner; B Steger; L Scharinger; D Lederer; A Mayr; M Strasser; E Brunner; A Heuberger; F Hohla; J Steinwendner; W Patsch; C Datz Journal: J Intern Med Date: 2011-04-25 Impact factor: 8.989
Authors: L B Yanoff; C M Menzie; B Denkinger; N G Sebring; T McHugh; A T Remaley; J A Yanovski Journal: Int J Obes (Lond) Date: 2007-04-17 Impact factor: 5.095
Authors: Jeffrey D Browning; Lidia S Szczepaniak; Robert Dobbins; Pamela Nuremberg; Jay D Horton; Jonathan C Cohen; Scott M Grundy; Helen H Hobbs Journal: Hepatology Date: 2004-12 Impact factor: 17.425
Authors: Daniel R Crooks; Nunziata Maio; Andrew N Lane; Michal Jarnik; Richard M Higashi; Ronald G Haller; Ye Yang; Teresa W-M Fan; W Marston Linehan; Tracey A Rouault Journal: J Biol Chem Date: 2018-03-09 Impact factor: 5.157
Authors: Jürgen Stein; Susan Connor; Garth Virgin; David Eng Hui Ong; Lisandro Pereyra Journal: World J Gastroenterol Date: 2016-09-21 Impact factor: 5.742
Authors: Laurence Britton; Kim Bridle; Janske Reiling; Nishreen Santrampurwala; Leesa Wockner; Helena Ching; Katherine Stuart; V Nathan Subramaniam; Gary Jeffrey; Tim St Pierre; Michael House; Joel Gummer; Robert Trengove; John Olynyk; Darrell Crawford; Leon Adams Journal: Hepatol Commun Date: 2018-04-27